1. Introduction {#s0005}
===============

Currently, the diagnosis of Alzheimer\'s disease (AD) combines clinical criteria with biological markers reflecting the pathological changes in the brain ([@bb0070]; [@bb0170]). Determination of biomarkers that can predict the clinical progression to AD is of utmost importance to accurately identify at-risk subjects for enrichment of disease-modifying treatment trials ([@bb0125]). In particular, the amnestic subtype of mild cognitive impairment (aMCI) is associated with an increased risk of developing AD, corresponding to an annualized conversion rate of 30% ([@bb0210]; [@bb0230]). In this respect, AD conversion prediction over a shorter time span, i.e. one or two years, can be considered clinically relevant, especially to identify rapid versus slow AD progressors.

The most accepted hypothetical model for the development of AD suggests a temporal order of the pathological changes in which amyloidosis triggers tau spreading outside of the medial temporal cortex, subsequently leading to the neurodegenerative processes and cognitive deterioration ([@bb0105]). However, the causal role of amyloid in the etiology of AD pathogenesis (amyloid cascade hypothesis) remains elusive and some argue for a tau-centric pathway or a synergistic interaction between amyloid and tau ([@bb0115]). In 2018, the NIA-AA research framework 'A/T/N' was established which avoids the assumptions of the temporal ordering of the biomarkers ([@bb0120]). Herein, AD is defined as a continuous process in both cognitive and biomarker domains rather than as three separate clinical entities (i.e., preclinical, MCI, and dementia). The 'A+' in A/T/N refers to fibrillary Aβ deposition quantified as high retention on amyloid-PET or low Aβ~1--42~/Aβ~1--40~ levels in the cerebrospinal fluid (CSF) ([@bb0025]; [@bb0095]), 'T+' refers to tau pathology characterized by elevated CSF phosphorylated tau levels (P-tau~181~) or tau-PET uptake ([@bb0190]; [@bb0270]), and 'N+' reflects synaptic dysfunction and neuronal degeneration based on decreased ^18^F-fluorodeoxyglucose (^18^F-FDG) PET uptake, atrophy on magnetic resonance imaging (MRI) or elevated CSF total tau (T-tau) ([@bb0110]; [@bb0135]). Thus, complete A/T/N characterization is possible using CSF or imaging biomarkers alone, as well as using a combination of both. However, the disagreement between biomarker modalities within the different A/T/N categories may introduce bias when individual subjects are classified as positive or negative ([@bb0100]). Moreover, these modalities (CSF/imaging) may not be fully interchangeable when predicting cognitive decline or MCI-to-AD conversion. Indeed, whereas amyloid-PET was found to be a predictor of future cognitive decline ([@bb0015]; [@bb0065]; [@bb0080]; [@bb0145]), CSF Aβ had a rather limited prognostic value ([@bb0015]; [@bb0050]; [@bb0290]). Lastly, an extra level of variability may be introduced within one modality when using the CSF Aβ~1--42~/Aβ~1--40~ ratio instead of Aβ~1--42~ alone ([@bb0180]), or when selecting different reference regions for amyloid-PET standardized uptake value ratio (SUVR). For example, changes in ^18^F-florbetapir (^18^F-AV45) SUVR normalized to a white matter reference region were shown to be better associated with changes in cognition compared to applying a cerebellar or pontine reference region ([@bb0040]).

In contrast to the A+ and T+ biomarkers, the markers of neurodegeneration cannot be used to indicate Alzheimer\'s pathophysiologic processes ([@bb0120]) as they are known to show topographical overlap with non-AD pathologies ([@bb0305]). However, structural and metabolic abnormalities correlate well with the symptom severity as they become present in closer proximity to the onset of cognitive decline ([@bb0045]; [@bb0105]; [@bb0145]; [@bb0140]; [@bb0200]; [@bb0250]; [@bb0290]; [@bb0310]). Indeed previous literature have suggested their utility as predictors of short-term MCI-to-AD dementia conversion ([@bb0085]; [@bb0090]; [@bb0140]; [@bb0200]; [@bb0275]; [@bb0310]), although with limited interchangeability ([@bb0100]).

Despite extensive literature on the associations between biomarkers and cognition, only few clinical trials and observational studies performed a complete A/T/N characterization of their participants included, using different biomarker modalities within the different categories ([@bb0075]; [@bb0220]; [@bb0300]). Therefore, in the present study, we aimed to investigate which A/T/N biomarkers (except for tau-PET) at baseline were associated with short-term cognitive decline in a population comprising the whole spectrum of AD, including cognitively healthy controls (HC), MCI, and AD dementia patients. Secondly, we determined which of the baseline biomarkers could discriminate MCI-to-AD dementia converters from non-converters.

2. Materials and methods {#s0010}
========================

2.1. Study population {#s0015}
---------------------

Seventy-eight subjects were enrolled in the study, including 13 HC, 49 MCI and 16 AD dementia patients. They underwent ^18^F-AV45 PET, ^18^F-FDG PET, lumbar puncture, MRI, and an extensive neuropsychological examination at baseline. ^18^F-AV45-PET was repeated after one year, whereas the cognitive battery was repeated after one and two years. The number of subjects per biomarker measure (both at baseline and follow-up) is listed in [Table 1](#t0005){ref-type="table"}.Table 1Number (and percentage, %) of subjects per biomarker measure at baseline and follow-up, and amount of follow-up days.Table 1HC (*N* = 13)MCI (*N* = 49)AD dementia (*N* = 16)*Biomarker*BLFUdays ± SDBLFUdays ± SDBLFUdays ± SDCognition[a](#tf0005){ref-type="table-fn"}*year 1*13 (100)12 (92)417 ± 3349 (100)37 (76)413 ± 11416 (100)13 (81)407 ± 80*year 2*10 (77)792 ± 4017 (35)726 ± 78\*6 (38)737 ± 40AV45-PET13 (100)----49 (100)19 (39)373 ± 1316 (100)4 (25)407 ± 52FDG-PET13 (100)----48 (98)----16 (100)----CSF7 (54)----45 (92)----15 (94)----MRI13 (100)----47 (96)----16 (100)----[^2][^3][^4]

Categorization into diagnostic groups was made on a demographical and clinical basis (not biomarker-based) by consensus of three expert medical doctors (SE, TVDB, SVM). The panel made a consensus clinical diagnosis of 'dementia due to AD' (AD dementia) by applying the NIA-AA criteria ([@bb0170]). A consensus diagnosis of 'MCI due to AD' (MCI) was based on the NIA-AA criteria ([@bb0005]), i.e. (1) cognitive complaint, preferably corroborated by an informant; (2) objective cognitive impairment, quantified as performance of \>1.5 standard deviation (SD) below the appropriate mean on the neuropsychological subtests; (3) largely normal general cognitive functioning; (4) essentially intact activities of daily living (basic and instrumental activities of daily living were determined by a clinical interview with the patient and an informant); and (5) not demented. The inclusion criteria for HC were: (1) no neurological or psychiatric antecedents; (2) no organic disease involving the central nervous system following extensive clinical examination; and (3) normal neuropsychological exam. Exclusion criteria for the total population consisted of brain tumors, large cerebral infarction/bleeding, strategic infarctions, other neurodegenerative diseases, severe head trauma, epilepsy, brain infections, severe depression, unregulated diabetes mellitus, untreated thyroid disorders, or any severe somatic co-morbidity that interferes with study participation.

HC consisted of volunteers, mainly spouses of patients who visited the memory clinic. Patients were recruited through the Memory Clinic of ZNA Middelheim and Hoge Beuken, Antwerp, Belgium. They were clinically followed-up by the neurologist every six months. The conversion from MCI to AD dementia was based on the clinical non-biomarker-based diagnoses and was established using the clinical diagnostic dementia criteria (as described above). This included a decline in instrumental activities of daily living (IADL; lower scores indicate more problems with daily life activity) questionnaire, preferable reported by the caregiver.

Approval for the study was obtained from the Committee for Medical Ethics of the University of Antwerp/University Hospital Antwerp (14/12/130) and of Hospital Network Antwerp (ZNA) (4310), and all participants or their representatives provided informed consent.

2.2. Neuropsychological investigation {#s0020}
-------------------------------------

All patients underwent a neuropsychological examination, including the Mini-Mental State Examination (MMSE) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) which is composed of the immediate memory, delayed memory (subtests: word list recall, story recall, figure recall, word list recognition), language, attention, and visuospatial construction (figure copy and judgment of line orientation) index scores. The raw scores of the RBANS were converted to z-scores based on the norm scores. These normative z-scores of the separate RBANS domains were dichotomized by using a − 1.5 SD cut-off (no cognitive deficit versus cognitive deficit).

2.3. CSF biomarkers {#s0025}
-------------------

CSF collection and processing methods are described elsewhere ([@bb0180]). CSF concentrations of Aβ~1--42~, Aβ~1--40~, T-tau, and P-tau~181~ were determined with commercially available single-analyte ELISA (INNOTEST® β-AMYLOID(1--42), β-AMYLOID(1--40), hTAU-Ag, and PHOSPHO-TAU(181P), respectively; Fujirebio Europe) as routinely performed in the BIODEM lab ([@bb0245]). The laboratory technician performing the biomarker analyses was blinded to clinical diagnosis. In addition, the Aβ~1--42~/Aβ~1--40~, Aβ~1--42~/T-tau, and Aβ~1--42~/P-tau~181~ ratios were calculated. CSF biomarker results were not included in the consensus clinical diagnosis made by the panel.

2.4. Imaging biomarkers {#s0030}
-----------------------

Procedures for acquisition of PET and MRI images are described in ([@bb0195]). Baseline and follow-up PET scans were coregistered to baseline MRIs for each subject using PMOD v3.6 (PMOD Technologies Ltd., Zurich, Switzerland). Regions of interest were delineated based on brain parcellation of the anatomic MRIs using automated knowledge-based grey matter/white matter/CSF segmentation in PMOD. ^18^F-FDG SUVRs were derived from a static scan at 30--40 min post-injection and calculated in the precuneus and posterior cingulate cortex (PCC) target regions with a cerebellar grey matter reference region. Regional ^18^F-AV45 SUVRs were derived at 50--60 min post-injection and normalized to either the cerebellar grey (SUVR~CB~) or the whole subcortical white matter (SUVR~WM~). A global cortical ^18^F-AV45 SUVR was calculated as the volume-weighted average uptake in the frontal, temporal and parietal lobe. The longitudinal change in SUVR was computed as ΔSUVR = (SUVR~FU~-SUVR~BL~)/SUVR~BL~^⁎^100 (with BL: baseline; FU: follow-up) and therefore expressed as a percentage, enabling comparison between different reference regions despite their different scales. All data was corrected for partial volume effects based on the region-based geometric transfer matrix method (GTM as described by ([@bb0205])) and a 5x5x5mm PET scanner resolution.

MRI volumes, including hippocampal volume (HV), cortical grey matter volume (CGM), and white matter hyperintensity volume (WMH), were extracted by ico**metrix**, using the CE-labelled and FDA-cleared software IcoBrain. The processing method is described elsewhere ([@bb0185]; [@bb0240]). All volumes were normalized to total head size.

2.5. Biomarker positivity {#s0035}
-------------------------

All continuous biomarker values at baseline were also dichotomized as positive (i.e., suggestive for AD) or negative.

Two dichotomous measures of CSF status were generated, one based on the Aβ~1--42~/Aβ~1--40~ ratio and one based on the Aβ~1--42~/T-tau ratio. The CSF biomarker profile was considered to be positive if the Aβ~1--42~/Aβ~1--40~ value was below the cut-off (\<0.067 pg/mL) or the Aβ~1--42~/T-tau value was below the cut-off (\<2.153 pg/mL). The cut-off values were in-house validated in autopsy-confirmed AD versus HC ([@bb0245]).

^18^F-FDG-PET biomarker positivity was defined using the automated quantitative analysis software MIMneuro (MIM Software Inc. Cleveland, OH), comparing each subject\'s scan on a voxel-by-voxel basis to a normal database comprising 43 HC. All images were normalized to the mean activity in the whole brain, pons, and cerebellum.

Two dichotomous measures of amyloid status were generated, one based on the visual PET reading and the other one using a quantitative cortical SUVR threshold. Both were described previously ([@bb0180]). The first measure used a database-assisted analysis in which the ^18^F-AV45 uptake pattern of all subjects was compared to a normal pattern on a voxel-by-voxel basis allowing for calculation of z-scores. The brain norm was created from a set of SUVR images acquired with Aβ-negative HC (*N* = 9) and normalized to the CB. The second measure used a receiver operating characteristic (ROC) area under the curve (AUC) analysis using the SUVR~CB~ and SUVR~WM~ values of HC and AD dementia patients (cortical SUVR~CB~ threshold = 1.203; SUVR~WM~ threshold = 0.485).

MRI biomarker positivity was visually assessed by consensus of the clinical panel and was based on the presence or absence of hippocampal atrophy using the axial T1 image ([@bb0225]).

2.6. Statistical analysis {#s0040}
-------------------------

Statistical analyses were performed in IBM SPSS Statistics v24 and parameters were described as mean ± SD. Significance was determined at *p* \< 0.05. Differences among diagnostic groups were assessed using χ^2^ tests for categorical variables and Kruskal-Wallis tests with Bonferroni correction for continuous variables. The difference in cortical ^18^F-AV45 uptake between baseline and follow-up was tested using a Wilcoxon signed rank test.

### 2.6.1. Regression analyses {#s0045}

Associations between cognition and the other biomarkers at baseline were assessed for each biomarker separately, using general linear modeling corrected for the covariates age, sex, education, *APOE* ε4 genotype, and baseline clinical diagnosis. For the association of Δcognition with baseline biomarkers, the covariates baseline cognition score and cognition time interval were added to the model. *Z*-scores were used to calculate standardized regression coefficients (β), allowing to compare the strength of the associations between (change in) cognition and the other biomarkers at baseline. The Benjamini-Hochberg procedure was used as False Discovery Rate (FDR) multiple comparisons correction for *p*-values across the 8 cognitions, using an FDR adjusted *p*-value of 0.05. In addition, model robustness was confirmed based on nonparametric bootstrapping with 1000 resamples and the 95% confidence intervals (C.I.) of the standardized βs that excluded zero (JMP Pro v14, SAS Institute Inc., USA). Regression analyses between ΔSUVR and SUVR at baseline were likewise assessed using general linear modeling corrected for the covariates age, sex, education, *APOE* ε4 genotype, baseline diagnosis, and PET time interval.

Lastly, linear mixed-effects regression analyses were conducted with the dichotomous ^18^F-FDG, MRI, CSF (Aβ~1--42~/Aβ~1--40~, Aβ~1--42~/T-tau) or ^18^F-AV45 status at baseline, time (baseline and 2 follow-up cognition time points) and the time-by-status interaction entered, to determine whether biomarker positivity was associated with changes in each of the cognitive measures over 1 and 2 years. The significance of the interaction term entailed whether biomarker positivity had a significant effect on cognitive change over time. All models included age, sex, education, and *APOE* ε4 genotype as covariates, as well as a random intercept to account for individual differences in cognition at baseline.

### 2.6.2. MCI-to-AD dementia conversion {#s0050}

^18^F-AV45-PET, ^18^F-FDG-PET, MRI (CGM, HV, WMH), CSF (all continuous measures), and cognition scores as well as demographic data obtained in MCI patients were used to determine conversion to AD dementia after 1 year. The Mann-Whitney *U* test with FDR multiple comparisons correction was used to assess differences between converters and non-converters on each of the biomarker measures at baseline. In addition, binary logistic regression was conducted to determine the most optimal combination of variables to discriminate converters from non-converters, and was conducted as following. First, regression analyses were conducted separately for each of the variables (one-variable model). Next, two-variable models were created by adding a significant single variable to the one-variable models. Only those combinations that could significantly improve the discriminative ability of the one-variable model were considered (χ^2^ test between log-likelihoods). Lastly, a third variable was added to the two-variable models in a similar way to build three-variable models. AUCs between models were compared using the AUC comparison function in JMP. Assumptions of the multiple variable models were met: 1) no collinearity between variables (e.g., three-variable model: variance inflation factor \< 2, Pearson\'s *r* \< 0.6), and 2) linear relationship between the variables and their log odds (Box-Tidwell test). For all analyses, the predictive power was evaluated through ROC analysis (probability cut-off = 50%). Sensitivity and specificity of the models were calculated. Sample sizes varied slightly between the different regression models due to missing data.

3. Results {#s0055}
==========

3.1. Demographics {#s0060}
-----------------

[Table 2](#t0010){ref-type="table"} represents the demographic and biomarker data at baseline, grouped by clinical diagnosis. No differences between diagnostic groups were found in sex and *APOE* ε4 genotype. The MCI and AD dementia group showed significantly higher ^18^F-AV45 and lower ^18^F-FDG PET uptake, more cognitive impairment, and smaller HV compared to the HC group. Additionally, the AD dementia group showed significantly higher CSF T-tau, lower Aβ~1--42~/T-tau and Aβ~1--42~/P-tau~181~, as well as smaller CGM and more WMH compared to the HC group. Differences in CSF P-tau~181~ and Aβ~1--42~/Aβ~1--40~ between HC and AD dementia showed a trend towards statistical significance. The percentage of Aβ-PET positive subjects increased across diagnostic groups (31% HC, 80% MCI, 100% AD dementia based on the cortical SUVR~CB~ cut-off). Similarly, the percentage of CSF and MRI positive subjects also increased (CSF: 43% HC, 78% MCI, 93% AD dementia based on the Aβ~1--42~/Aβ~1--40~ cut-off, and 29% HC, 64% MCI, 93% AD dementia based on the Aβ~1--42~/T-tau cut-off; MRI: 15% HC, 71% MCI, 75% AD dementia based on visual reading).Table 2Demographics at baseline.Table 2VariableHC (N = 13)MCI (N = 49)AD dementia (N = 16)Female sex, %624350Age at baseline PET, years67.18 ± 7**72.74 ± 8 \***73.54 ± 7Education, years18.23 ± 415.63 ± 5**14.44 ± 3 \****APOE* ε4 carriers, % (*N*)45 (5/11)66 (27/41)79 (11/14)  Amyloid-PETCortical SUVR~CB~ (%Aβ+)1.31 ± 0.4 (31)**1.77 ± 0.6 \*** (80)**1.75 ± 0.3 \*** (100)Cortical SUVR~WM~ (%Aβ+)0.58 ± 0.2 (38)**0.76 ± 0.2 \*** (83)**0.79 ± 0.2 \*** (100)  ^18^F-FDG-PETPrecuneus SUVR (*N*)1.37 ± 0.09 (13)1.31 ± 0.17 (47)1.27 ± 0.17 (16)PCC SUVR (*N*)1.56 ± 0.15 (13)**1.37 ± 0.29 \*** (48)**1.28 ± 0.16 \*** (16)  CognitionMMSE (*N*)28.85 ± 1.72 (13)**25.18 ± 2.75 \*** (49)**22.38 ± 4.30** \* (16)  RBANS, z (*N*)Delayed memory+0.54 ± 1.07 (13)**−2.26 ± 1.11 \*** (48)**−3.32 ± 0.55 \***^**,\$**^ (14)*List recall*+0.45 ± 1.10 (13)**−1.59 ± 0.84 \*** (44)**−2.05 ± 0.46 \*** (15)*Story recall*+0.82 ± 1.05 (13)**−2.17 ± 1.41 \*** (44)**−2.86 ± 1.26 \*** (15)*Figure recall*+0.35 ± 1.20 (13)**−1.67 ± 1.23 \*** (44)**−2.55 ± 0.69 \*** (15)Immediate memory+0.74 ± 1.20 (13)**−1.61 ± 0.96 \*** (48)**−2.29 ± 0.69 \*** (14)Language+0.03 ± 0.71 (13)**−0.97 ± 0.85 \*** (46)**−1.75 ± 0.95 \***^**,\$**^ (14)Visuospatial construction+0.79 ± 0.88 (13)+0.05 ± 1.13 (44)**−0.71 ± 1.40 \*** (13)  CSF*N* subjects74515Aβ~1--42~/Aβ~1--40~, pg/mL0.07 ± 0.030.06 ± 0.030.04 ± 0.02Aβ~1--42~, pg/mL1114.06 ± 440771.34 ± 356643.47 ± 122Aβ~1--40~, pg/mL16,291.06 ± 432014,338.88 ± 391116,131.00 ± 4864T-tau, pg/mL329.14 ± 118451.67 ± 188**710.80 ± 372 \***P-Tau~181~, pg/mL61.87 ± 1873.40 ± 2493.14 ± 37Aβ~1--42~/T-tau, pg/mL3.95 ± 2.302.24 ± 1.82**1.32 ± 1.19 \***Aβ~1--42~/P-tau~181~, pg/mL19.89 ± 9.9412.41 ± 8.79**8.68 ± 6.29 \***  MRI*N* subjects134716Hippocampal volume, mm^3^8422.51 ± 43**7136.66 ± 1074 \*6666.81 ± 899 \***Cortical GM volume, ml767.85 ± 43735.46 ± 38**723.64 ± 44 \***WMH, ml5.03 ± 513.95 ± 17**14.34 ± 13 \***[^5][^6][^7]

3.2. Cognition and longitudinal cognitive decline {#s0065}
-------------------------------------------------

[Table 3](#t0015){ref-type="table"} shows the effect sizes of the associations between cognition and the other biomarkers, all at baseline. Higher cortical amyloid deposition, hypometabolism in the PCC, and smaller HV are significantly associated with more cognitive impairment. Lower CSF Aβ~1--42~ and Aβ~1--42~/P-tau~181~ levels were associated with reduced RBANS delayed memory (figure recall) index score, whereas the other CSF measures did not survive FDR correction.Table 3Associations of baseline cognition with other biomarkers (^18^F-AV45-PET, ^18^F-FDG-PET, MRI, CSF) at baseline.Table 3Baseline cognitionAV45FDGMRICSFCortical SUVR~CB~Cortical SUVR~WM~PCC SUVRHVAβ~1--42~Aβ~1--42~/P-tau~181~MMSE−0.21 (0.099)−0.15 (0.235)**+0.34 (0.004)**+0.16 (0.258)−0.03 (0.866)+0.10 (0.433)Delayed memory−0.23 (0.017)**−0.26 (0.005)+0.33 (\<0.001)+0.38 (\<0.001)+0.32 (0.005)**+0.25 (0.019)*List recall***−0.29 (0.004)−0.23 (0.016)+0.27 (0.004)+0.28 (0.010)**+0.24 (0.026)+0.13 (0.188)*Story recall***−0.34 (0.002)−0.25 (0.022)**+0.12 (0.255)+0.21 (0.100)+0.23 (0.070)+0.12 (0.328)*Figure recall***−0.36 (0.002)−0.40 (\<0.001)+0.32 (0.004)+0.33 (0.011)+0.36 (0.008)+0.40 (0.001)**Immediate memory**−0.29 (0.002)−0.34 (\<0.001)**+0.19 (0.042)+0.11 (0.310)+0.20 (0.084)+0.16 (0.125)Language−0.15 (0.258)−0.13 (0.319)+0.02 (0.872)−0.11 (0.459)+0.23 (0.105)+0.21 (0.103)Visuospatial construction−0.31 (0.038)−0.18 (0.221)+0.20 (0.163)**+0.37 (0.022)**−0.02 (0.889)−0.12 (0.455)[^8][^9]

[Table 4](#t0020){ref-type="table"} shows the effect sizes of the associations between change in cognition and the other biomarkers at baseline. Hypometabolism in the PCC and smaller HV at baseline are significantly associated with more cognitive decline after 1 year.Table 4Associations of 1-year cognitive decline (Δ) with other biomarkers (^18^F-FDG-PET, MRI) at baseline.Table 4ΔcognitionFDGMRIPCC SUVRHVΔMMSE+0.19 (0.286)**+0.47 (0.010)**ΔDelayed memory**+0.55 (0.003)**+0.46 (0.044)*ΔList recall***+0.31 (0.020)**+0.27 (0.076)*ΔStory recall***+0.43 (\<0.001)+0.37 (0.005)***ΔFigure recall***+0.37 (0.008)**+0.31 (0.052)ΔImmediate memory+0.26 (0.120)+0.14 (0.439)ΔLanguage+0.08 (0.563)+0.36 (0.019)ΔVisuospatial construction+0.09 (0.601)−0.07 (0.711)[^10][^11][^12]

### 3.2.1. Influence of reference region selection for AV45 SUVR {#s0070}

When Aβ deposition was quantified as cortical SUVR referenced to WM, higher baseline SUVR~WM~ was significantly associated with more cognitive decline over time (Δ delayed recall β = −0.40 (*p* = 0.029); Δ list recall β = −0.29 (*p* = 0.028); Δ story recall β = −0.28 (*p* = 0.020)), though none of the *p*-values survived FDR-correction. No associations were found for reference CB. The superior performance of WM normalization compared to CB normalization became also clear when 1-year changes in SUVR were investigated in a subset of our MCI and AD dementia patients with a follow-up PET scan (*N* = 23). Firstly, global cortical ^18^F-AV45 SUVR~WM~ was significantly increased at 1-year follow-up compared to baseline (+2.61 ± 4% on average over all subjects, *p* = 0.015), in contrast to SUVR~CB~ (+2.33 ± 9%, *p* = 0.412). Secondly, the number of subjects that showed a (contra-intuitively) SUVR decline over time (ΔSUVR \< −0.5%) was smaller for reference WM compared to CB (17% versus 35% of the cases). Lastly, higher baseline ^18^F-AV45 SUVR~WM~ was significantly (*p* = 0.05) associated with smaller increases in SUVR~WM~ (i.e., ΔSUVR~WM~) over time. This most likely indicates that amyloid accumulation slowed down in the clinical phase (Supplementary Fig. 1). There was no such association for reference CB (*p* = 0.38).

### 3.2.2. Influence of biomarker positivity on longitudinal cognitive changes {#s0075}

All biomarker positive groups (except CSF) at baseline showed significantly faster decline (time-by-status interaction) in MMSE and RBANS delayed memory index score over 2 years compared to their corresponding negative group ([Table 5](#t0025){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}). The ^18^F-FDG- and ^18^F-AV45-positive group (based on visual reading) also showed a faster 1-year decline in MMSE and delayed memory index score, respectively, compared to the negative group.Table 5Difference in the rate of cognitive change over 2 years between positive and negative ^18^F-FDG-, ^18^F-AV45-, or MRI-groups at baseline.Table 5FDGAV45MRIReadQuantitativeReadRead*SUVR*~*CB*~*SUVR*~*WM*~MMSE**+0.42 (\<0.001)+0.33 (0.004)+0.34 (0.005)+0.27 (0.011)+0.27 (0.012)**Delayed memory**+0.17 (0.014)**+0.14 (0.024)**+0.16 (0.011)+0.19 (0.001)+0.14 (0.022)***List recall*+0.12 (0.222)**+0.24 (0.004)+0.31 (\<0.001)+0.21 (0.012)**+0.12 (0.172)*Story recall*+0.06 (0.589)+0.15 (0.093)+0.02 (0.801)+0.12 (0.197)**+0.23 (0.012)***Figure recall*+0.09 (0.388)+0.11 (0.231)+0.14 (0.137)+0.02 (0.820)+0.06 (0.542)Immediate memory+0.19 (0.058)+0.17 (0.051)+0.16 (0.079)+0.11 (0.233)+0.18 (0.040)Language+0.27 (0.013)−0.006 (0.954)−0.02 (0.883)−0.01 (0.900)+0.26 (0.009)Visuospatial construction+0.01 (0.925)+0.10 (0.456)+0.03 (0.794)+0.08 (0.509)+0.11 (0.373)[^13][^14][^15]Fig. 1Trajectories of MMSE and RBANS delayed memory index score over 2 years grouped by ^18^F-FDG (A, B) and ^18^F-AV45 (C, D) positivity based on visual reading at baseline. The Δslope (non-standardized β) indicates the difference in change in cognitive score per year between PET+ and PET- subjects, adjusted for covariates. Abbreviations: *CI* confidence interval, *MMSE* Mini-Mental state examination, *PET* positron emission tomography, *SE* standard error.Fig. 1

3.3. MCI-to-AD dementia conversion {#s0080}
----------------------------------

### 3.3.1. Baseline characteristics of converters versus non-converters {#s0085}

Of the 42 MCI patients with a follow-up clinical diagnosis, 15 patients progressed to AD dementia at the time of the first follow-up (mean follow-up time was 415 ± 18 days), corresponding to an annual conversion rate of 31%. The groups of converters versus non-converters were not different with respect to age, sex, *APOE* ε4 genotype, education, ^18^F-AV45-PET, and CSF levels. There was a significant difference in baseline MMSE (*p* = 0.023), RBANS delayed memory index score (*p* = 0.022), RBANS visuospatial construction index score (*p* = 0.007), HV (*p* \< 0.0001), CGM volume (*p* = 0.002), and ^18^F-FDG-PET in the precuneus (*p* \< 0.0001) between both groups ([Fig. 2](#f0010){ref-type="fig"}). However, after FDR-correction, only HV, CGM, and ^18^F-FDG-PET remained significant.Fig. 2Baseline cognitive scores (A), regional ^18^F-FDG uptake (B), and MRI-based HV and CGM (C) in MCI-to-AD dementia converters (blue) versus non-converters (black) after 1 year follow-up. Error bars correspond to standard deviation. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\*\* *p* \< 0.0001. Abbreviations: *CGM* cortical grey matter volume, *HV* hippocampal volume, *MMSE* Mini-Mental state examination, *PCC* posterior cingulate cortex, *PET* positron emission tomography, *SUVR* standardized uptake value ratio. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2

### 3.3.2. Prediction of MCI-to-AD dementia conversion {#s0090}

Based on binary logistic regression (dependent variable: conversion within 1 year), significant single independent variables that could predict conversion included HV (odds ratio (OR) = 0.107, 95% C.I.: \[0.025--0.453\], *p* = 0.002), CGM (OR = 0.198, 95% C.I.: \[0.062--0.632\], *p* = 0.006), ^18^F-FDG-PET (OR = 0.162, 95% C.I.: \[0.048--0.547\], *p* = 0.003), and cognition (RBANS visuospatial construction index score: OR = 0.389, 95% C.I.: \[0.186--0.812\], *p* = 0.012; RBANS delayed memory index score: OR = 0.434, 95% C.I.: \[0.211--0.896\], *p* = 0.024; MMSE: OR = 0.748, 95% C.I.: \[0.573--0.977\], *p* = 0.033).

HV was the strongest single variable based on its highest AUC of 0.89 (95% C.I.: \[0.80--0.99\], sensitivity: 64%, specificity: 89%), and approximately 51.7% explained variance (Nagelkerke R^2^) ([Fig. 3](#f0015){ref-type="fig"}A). Addition of CGM or ^18^F-FDG-PET to the single-variable model of HV resulted in an AUC of 0.92 (95% C.I.: \[0.83--1.00\], sensitivity: 71%, specificity: 89%) and 0.91 (95% C.I.: \[0.82--1.00\], sensitivity: 86%, specificity: 92%), respectively ([Fig. 3](#f0015){ref-type="fig"}A). However, the increases in AUC of the two- versus one-variable models were non-significant. The highest 2-variable AUC was reached for a combination of the RBANS visuospatial construction index score and either HV or ^18^F-FDG-PET ([Fig. 3](#f0015){ref-type="fig"}B). Their AUCs significantly increased (*p* = 0.023 and *p* = 0.030, resp.) compared to the one-variable model with visuospatial construction skills only. The combination of HV, ^18^F-FDG-PET and visuospatial construction skills resulted in the strongest three-variable model with an AUC of 0.99 (95% C.I.: \[0.96--1.00\], sensitivity: 92%, specificity: 96%) ([Fig. 3](#f0015){ref-type="fig"}B). However, the increase in AUC compared to the two-variable models was non-significant. All significant one-, two- and three-variable(s) combinations are reported in Supplementary Table 1, together with their AUC, accuracy, sensitivity and specificity.Fig. 3Receiver operating characteristic curves of the strongest (i.e., highest AUC) one-, two- and three- variable models describing MCI-to-AD dementia conversion over 1 year (*N* = 42). Panel A (left column) shows the strongest single imaging biomarker variables, whereas panel B (left column) shows the strongest single cognitive variables. The middle and right columns show the two- and three-variable models for which the discriminating ability significantly improved after addition of an extra biomarker. Abbreviations: *AUC* area under the curve, *CGM* cortical grey matter volume, *Delayed* RBANS delayed memory index score, *FDG* 18F-fluorodeoxyglucose PET in the precuneu*s*, *HV* hippocampal volume, *MMSE* Mini-Mental state examination, *Visuo* RBANS visuospatial construction index score.Fig. 3

4. Discussion {#s0095}
=============

The current study investigated the utility of the A/T/N biomarkers (A: CSF Aβ and ^18^F-AV45-PET; T: CSF P-tau~181~; N: CSF T-tau, MRI atrophy and ^18^F-FDG-PET) with respect to concurrent cognitive function, cognitive decline and MCI-to-AD dementia conversion over 1 year. In line with literature ([@bb0045]; [@bb0145]; [@bb0140]; [@bb0200]; [@bb0250]; [@bb0290]; [@bb0310]) we found that the neurodegenerative markers, including MRI-based HV and FDG-based hypometabolism in the posterior cingulate, were most strongly associated with baseline cognition and short-term cognitive decline. Moreover, HV and ^18^F-FDG-PET were the strongest single determinants of short-term conversion to AD dementia in the MCI group, corresponding to an accuracy of 80 and 83%, respectively. This is in line with accuracies of 66 to 83% that have been reported previously ([@bb0085]; [@bb0140]; [@bb0200]; [@bb0275]; [@bb0310]). The combination of ^18^F-FDG-PET and HV resulted in an accuracy of 90% in our study. This implies that both imaging modalities are yielding complementary information when interpreted together ([@bb0295]). The AD-like patterns of ^18^F-FDG hypometabolism and MRI atrophy develop according to a similar anatomic pattern and extent as the clinical features, explaining their direct relationship with cognition. However in clinical practice, it may be of greater interest to combine an imaging modality with a cognitive marker to predict conversion to AD dementia. In this respect, we found that the combination of a visuospatial construction score with either ^18^F-FDG-PET or MRI HV significantly improved AUCs and resulted in a predictive accuracy of 89% and 86%, respectively. A combination of all three markers resulted in the highest accuracy of 94% (96% specificity, 92% sensitivity). Research on visuospatial abilities is relatively scarce, though it has shown significant diagnostic and prognostic potential in dementia as concluded by a recent review paper ([@bb0215]). Unlike memory deficits, visuospatial deficits rely on the dysfunctioning of the parietal lobe, which is among the earliest manifestations of AD. The parietal lobe is involved in higher cognitive functions and highly vulnerable to metabolic impairment. Hence, cognitive testing for visuospatial functioning may be applied for differential diagnosis (discriminate AD dementia from non-AD dementias such as frontotemporal dementia) as well as for the prediction of MCI-to-AD dementia conversion. In addition, it seems possible that different subtypes in prodromal AD are related to other cognitive areas, and thus show different patterns of cognitive decline ([@bb0255]). Visuospatial functioning is associated with two subtypes of prodromal AD; the diffuse subtype in which cortical atrophy with intermediate clinical, cognitive and biological features are found, and also the subtype with pronounced parieto-occipital atrophy in combination with high CSF tau levels. On the other hand, combining MRI or ^18^F-FDG-PET with either RBANS delayed memory index score or MMSE corresponded to diagnostic accuracies between 76 and 80%, however the sensitivity was relatively low in our study (57--71%).

Biomarkers related to the early events of the pathological cascade (referring to A+ of the A/T/N model) showed that higher baseline cortical ^18^F-AV45 SUVR~WM~, notably in the parietal lobe and precuneus (data not shown), was associated with faster cognitive decline, irrespective of baseline clinical diagnosis. However, when conducted separately in the Aβ-PET positive group, we could not find a significant association between amyloid SUVR at baseline and cognitive decline (data not shown). These findings are in line with a previous study in a combined cohort of Aβ-PET positive and negative MCI patients ([@bb0060]), indicating that the presence of Aβ could be an important predictor of cognitive decline. On the other hand, the extent and anatomical pattern of Aβ deposition are known to show poor correlations to cognitive severity or disease progression ([@bb0260]). Therefore, the association between Aβ and cognitive deficit is most likely of an indirect origin, in which abnormal Aβ accumulation triggers downstream neurodegenerative processes that, on their turn, exert direct effect on cognition. This might also explain why amyloid-PET was significantly associated with short-term cognitive decline in our whole cohort, but could not discriminate short-term MCI-to-AD dementia converters from non-converters. Due to small sample sizes, we could however not perform within-diagnostic group analyses to test this hypothesis.

The association between baseline ^18^F-AV45 SUVR and ΔSUVR as well as Δcognition was only significant when a WM reference region was considered. Moreover, regional SUVR~WM~ but not SUVR~CB~ was significantly increased at follow-up in a subset of our clinical cohort, corresponding to +2--3% yearly. In contrast, Aβ deposition quantified by SUVR~CB~ was (unexpectedly) decreased over time in 35% of the cases. In 4 out of the 8 subjects with longitudinal declining cortical SUVR~CB~, SUV was more increased in the reference region than in the target region, questioning the use of CB as a reference region for longitudinal purposes. Several recent studies have suggested the superior performance of a WM reference region for the ^18^F-AV45 ligand, both in cross-sectional and longitudinal designs ([@bb0035]; [@bb0040]; [@bb0150]; [@bb0195]; [@bb0235]). This could be related to its more favourable location in the same axial plane as the neocortical target areas ([@bb0020]). However, a recent ^11^C-PiB study by ([@bb0155]) found WM uptake to be dependent on age and cortical Aβ deposition, thereby questioning its validity as a reference region. In our study, WM SUVR~CB~ changes were small (−0.1 ± 10%), most likely because of the relatively advanced stage of our clinical cohort with high amyloid load at baseline and the short follow-up time (1 year).

Considered as neurodegenerative markers, CSF T-tau and Aβ~1--42~/T-tau were not associated with cognitive decline nor were they predictors of conversion in our study. Previous studies found an association with cognitive decline ([@bb0015]; [@bb0075]; [@bb0130]) or conversion ([@bb0030]; [@bb0160]; [@bb0265]; [@bb0280]), whereas others did not ([@bb0050]; [@bb0290]). In line with ([@bb0285]), we found only a weak correlation between the CSF tau and MRI-based HV markers of neuronal injury (data not shown). Vemuri et al. ([@bb0265]) reported that MRI could be closer related to disease progression than CSF T-tau as the latter may be more prone to diurnal physiologic variations, therefore reflecting transient rather than cumulative damage. In general, we could not find good relationships between any of the CSF markers and cognition at baseline. It appeared from our analysis that the prediction of cognition by CSF markers could be explained by the link with disease state, as CSF (in particular T-tau and P-tau markers) disappeared from the model after we additionally corrected for clinical diagnosis. In contrast, amyloid-PET/CSF, ^18^F-FDG-PET, and HV retained an association with cognition even when diagnosis was considered. These findings were in line with the study by ([@bb0165]). Cognitive function is, by clinical diagnostic definition, lower for subjects with MCI/AD than for controls. Therefore, in an attempt to attend this potential confound and investigate the *independent* and *complementary* information of a single biomarker on cognitive function and cognitive decline in a larger cohort, we corrected for baseline diagnosis. Models without clinical diagnosis as a covariate can be found in Supplementary Table 2 and 3.

This study has a number of limitations. In our 1-year follow-up study, 15 out of 42 MCI patients (31%) converted to AD dementia, which is higher than the 8--16% expected annual risk of conversion ([@bb0140]; [@bb0175]). This can be explained by a high percentage of Aβ-PET positive (85%) and amnestic MCI subtypes (86%) in our cohort. Moreover, our MCI participants were recruited from a memory clinic rather than through community screening. Secondly, due to small sample size, we could not perform within-group regression analyses (i.e., investigate the effect of clinical phenotype \[non-amnestic vs amnestic MCI\] or clinical diagnostic group \[HC vs MCI vs AD dementia\] or A/T/N criteria). It is likely that for example CSF T-tau levels were associated with cognitive decline in the (non-converting) MCI subjects, but have reached a plateau in the later MCI/AD dementia phase. Thirdly, MCI subjects with clinical progression to unspecified dementias were included as it was not always possible to make the diagnosis of dementia due to AD solely on a clinical basis. A non-biomarker based diagnosis was performed in this study to avoid circular reasoning (i.e., the same tests are used to diagnose a disease and then to predict the diagnosis). However, the inclusion of unspecified dementia subjects may have decreased the predictive power of the biomarkers that were analyzed and may have increased the contribution of visuospatial construction score as a cognitive measure. Next, while we found that short-term (1 year) prognosis of AD conversion relates strongly to neurodegenerative markers, we could not find such association for amyloid-PET or -CSF biomarkers. Based on earlier findings ([@bb0055]), it is likely that longer-term prognosis (\> 2 years) in these individuals would be associated with a marker of amyloidosis. Lastly, ^18^F-FDG SUVR was normalized to a cerebellar reference region, although pons normalization has been applied in most of the previous literature. In our study however, automatic segmentation processes tend to fail in reliably separating the pons from the whole brainstem, most likely because the posterior border of this region was not well delineated on MRI ([@bb0010]). Moreover, cerebellar normalization has been recommended for ^18^F-FDG-PET by ([@bb0010]) as this region was least affected by metabolic changes in AD. Lastly, the pons may be more susceptible to noise and thus longitudinal variability, owing to its small size and sensitivity to head motion.

5. Conclusions {#s0100}
==============

Our results show that the neurodegenerative markers (MRI-based HV and ^18^F-FDG-PET) were strongly associated to cognitive decline and short-term (1-year) MCI-to-AD dementia conversion. The use of a neurodegenerative imaging marker in addition to a cognitive marker such as a visuospatial construction score could be applied in clinical practice to predict short-term conversion to AD dementia and for enrichment of disease-modifying treatment trials in MCI patients. CSF and amyloid-PET markers were not associated with short-term conversion. However, increased amyloid-PET uptake at baseline was associated with faster cognitive decline over time, only if SUVR was referenced to a WM reference region.
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[^1]: Shared first and last authors.

[^2]: Abbreviations: *AD* Alzheimer\'s disease, *BL* baseline, *CSF* cerebrospinal fluid, *FU* follow-up, *HC* cognitively healthy control, *MCI* mild cognitive impairment, *MRI* magnetic resonance imaging, *PET* positron emission tomography, *SD* standard deviation.

[^3]: \**p* \< 0.05 vs control subjects via Kruskal-Wallis corrected for multiple comparisons via Bonferroni.

[^4]: Cognition, i.e. at least MMSE measurement.

[^5]: Values are given as mean ± standard deviation.

[^6]: \* *p* \< 0.05 vs control subjects; ^\$^*p* \< 0.05 vs MCI subjects. Categorical variables (sex, *APOE* ε4) via Fisher\'s Exact test; continuous variables via Kruskal-Wallis corrected for multiple comparisons via Bonferroni. Significant *p*-values are shown in bold typeface.

[^7]: Abbreviations: *Aβ* *+* amyloid-beta positive, *AD* Alzheimer\'s disease, *APOE* gene encoding for apolipoprotein E, *CSF* cerebrospinal fluid, *GM* grey matter, *HC* cognitively healthy control, *MCI* mild cognitive impairment, *MMSE* Mini-Mental state examination, *MRI* magnetic resonance imaging, *PCC* posterior cingulate cortex, *PET* positron emission tomography, *P-tau*~*181*~ phosphorylated tau~181~, *SUVR*~*CB*~ standardized uptake value ratio normalized to cerebellar grey matter, *SUVR*~*WM*~ standardized uptake value ratio normalized to subcortical white matter, *T-tau* total tau, *WMH* white matter hyperintensities.

[^8]: Standardized regression coefficients β (and *p*-values) were retrieved from linear regression adjusted for age, sex, *APOE* ε4, education, and baseline clinical diagnosis. Significant associations that survived FDR-correction are shown in bold typeface. All biomarkers that only showed non-significant associations were omitted from the Table.

[^9]: Abbreviations: *CSF* cerebrospinal fluid, *HV* hippocampal volume, *MMSE* Mini-Mental state examination, *MRI* magnetic resonance imaging, *PCC* posterior cingulate cortex, *PET* positron emission tomography, *P-tau*~*181*~ phosphorylated tau~181~, *SUVR*~*CB*~ standardized uptake value ratio normalized to cerebellar grey matter, *SUVR*~*WM*~ standardized uptake value ratio normalized to subcortical white matter.

[^10]: Standardized regression coefficients β (and *p-*values) were retrieved from linear regression adjusted for age, sex, *APOE* ε4, education, baseline clinical diagnosis, baseline cognition, and cognition interval. Significant associations that survived FDR-correction are shown in bold typeface. All biomarkers that only showed non-significant associations were omitted from the Table

[^11]: Δcognition = Z~FU~ -- Z~BL~.

[^12]: Abbreviations: *HV* hippocampal volume, *MMSE* Mini-Mental state examination, *MRI* magnetic resonance imaging, *PCC* posterior cingulate cortex, *SUVR* standardized uptake value ratio.

[^13]: Standardized regression coefficients β (and *p-*values) were retrieved from linear mixed model analysis, adjusted for the covariates. Values in bold typeface represent a significant time-by-status interaction that survived FDR-correction, i.e. a significant faster cognitive decline in the biomarker positive versus negative group at baseline.

[^14]: ^18^F-FDG and MRI dichotomization (positive or negative) was based on visual reading, whereas ^18^F-AV45 dichotomization was based on either visual reading or a quantitative cut-off (SUVR~CB~ or SUVR~WM~). The CSF Aβ~1--42~/Aβ~1--40~ and Aβ~1--42~/T-tau ratios were omitted from the Table, as there were no significant interactions.

[^15]: Abbreviations: *MMSE* Mini-Mental state examination, *MRI* magnetic resonance imaging, *SUVR*~*CB*~ standardized uptake value ratio normalized to cerebellar grey matter, *SUVR*~*WM*~ standardized uptake value ratio normalized to subcortical white matter.
